Market Overview
The global age-related macular degeneration market is estimated to expand at 7.3 % CAGR during the forecast period (2017-2023) owing to the prevalence of diseases among the geriatric population. age-related macular degeneration (ARMD) is a disease of the retina where the sharp central vision gets blurred. The part of the retina, called macula which allows visualizing fine details is generally affected. A chronic disease that does not cause pain, AMD is majorly observed in patients above the age of 50.
Get Sample Report at https://www.marketresearchfuture.com/sample_request/5736
Future Drivers and Restraints Impacting the Market
The global marker for age-related macular degeneration is anticipated to reach USD 2,200 million by 2023. With the increasing prevalence of disease among the geriatric population, the market for age-related macular degeneration is estimated to propel over the forecast period. For instance, according to the Community Eye Health Journal which was published by London School of Hygiene and Tropical Medicine, around 196 million people are expected to suffer from AMD by 2020. Increasing awareness among the people has also influenced the treatment for AMD globally. Moreover, in third world countries, the emergence of off-patent blockbuster drugs is impacting the market positively. Additionally, growing healthcare expenditure and rising pipeline drugs for AMD are driving the market growth over the assessment period.
On the flipside, high cost of drugs and treatment along with lack of trained ophthalmologists are some of the major restraining factors inhibiting the market growth over the review period. Also, strict mandates and growing off-label use are also hindering the market growth over the years. For instance, a single injection of anti-vascular endothelial growth factor agent for treating AMD costs very high.
Competitive Analysis
Some of the key players operating the global market for age-related macular degeneration are Bayer AG, Regeneron Pharmaceutical Inc., Santen Pharmaceuticals, F. Hoffmann-La Roche AG, Novartis AG, and others.
Global Age-Related Macular Degeneration Market Segmentation
The global Age-Related Macular Degeneration Market for age-related macular degeneration has been segmented on the basis of route of administration, type, drug, treatment, end-user, and region.
By mode of type, the global market for age-related macular degeneration has been segmented into wet age-related macular degeneration and dry age-related macular degeneration. Among these, the wet age-related macular degeneration is more severe and causes abnormal progression of blood vessels in the damaged macula part which further causes the retinal vison to damage.
By mode of drug, the market has been segmented into Visudyne, Eylea, Avastin, Lucentis, and others.
By route of administration, the market has been segmented into intravitreal, intravenous, and others.
By mode of treatment, the global market for AMD has been segmented into devices, medication, surgery, and others. Among these, the medication segment is sub-segmented into anti-VEGF drugs, blood vessel growth inhibitors, dietary supplements, vitamins, and others. The devices segment has also been sub-segmented into glasses, corrective lenses, contact lenses, and others.
By mode of end-users, the market has been segmented into clinics, diagnostic centers and hospitals, academic research institutes, biotechnology companies and pharmaceuticals, and others.
North America to Hold the Largest Share
Geographically, the market for AMD spans across regions namely North America, Europe, Asia Pacific, and the Middle East & Africa.
North America is predicted to hold the largest market share due to the growing health concern and rising cases of macular degeneration. Around 1.8 million people are suffering from AMD in America and around 7.3 million people are at a significant risk of losing their vision due to AMD, asserts the Centers for Disease Control and Prevention (CDC).
Asia Pacific accounts for more than one-third of the macular generation cases and is expected to grow at a rapid pace than in America and Europe.
Industry News
Genentech, a member of the Roche Group has announced top line, positive results from the Phase II LADDER study evaluating the safety of its investigational Port Delivery System with ranibizumab in people suffering from wet age-related macular degeneration. The small, refillable eye implant, is slightly longer than a grain of rice, is designed to let people with wet AMD to go several months without needing to visit their ophthalmologist for treatment.
Access Report Details @ https://www.marketresearchfuture.com/reports/age-related-macular-degeneration-market-5736
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013,
No comments:
Post a Comment